A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers
Author:
Affiliation:
1. Samsung Bioepis Co., Ltd; Incheon Korea
2. PAREXEL International GmbH; Berlin Germany
Funder
Samsung Bioepis Co., Ltd.
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcpt.12583/fullpdf
Reference20 articles.
1. Societal cost of rheumatoid arthritis patients in the US;Birnbaum;Curr Med Res Opin,2010
2. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study;Cross;Ann Rheum Dis,2014
3. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?;Modena;Autoimmun Rev,2013
4. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update;Smolen;Ann Rheum Dis,2014
5. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial;Maini;Lancet,1999
Cited by 54 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers;International Journal of Pharmaceutics: X;2024-06
2. Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework;The AAPS Journal;2024-03-07
3. Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh;Discover Applied Sciences;2024-02-28
4. Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis;Ocular Immunology and Inflammation;2024-01-09
5. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases;Advances in Therapy;2023-12-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3